Gems from the poster halls are always a popular series at cancer conferences where we highlight emerging early stage agents of interest.

Not every oncology development has gone to the dogs – there are some gems out there too

This time around we look at some data from a China biotech, another peek at TIGIT, resistance to a targeted therapy, a novel antibody target and a real world study, which both inspired and caught my attention.

As always with oncology R&D it isn’s always plain sailing – there are sometimes some surprising results (good and bad), spanners in the works and also some really useful trial designs to consider.

What can we learn from the latest round of presentations?

Let’s roll!

To learn more about the early stage data and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by